Suppr超能文献

核黄素转运蛋白缺乏症病例报告:该基因中的一种新型杂合致病变异。

A case report of riboflavin transporter deficiency: A novel heterozygous pathogenic variant in the gene.

作者信息

Tranel Elizabeth S, McGowan Bridget, Drackley Andy, Epstein Leon G, Rao Vamshi K, Kuntz Nancy L, Schwaede Abigail N

机构信息

Division of Neurology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, United States of America.

Division of Genetics, Genomics and Metabolism, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, United States of America.

出版信息

Mol Genet Metab Rep. 2024 Jan 15;38:101051. doi: 10.1016/j.ymgmr.2024.101051. eCollection 2024 Mar.

Abstract

Riboflavin transporter deficiency (RTD) is a neurodegenerative disorder that presents from infancy to adulthood with a progressive axonal neuropathy characterized by a variety of neurologic symptoms including hearing loss, weakness, bulbar palsy, and respiratory insufficiency. Pathogenic variants in and are implicated in the pathogenesis of RTD type 2 and 3, respectively. Early identification of this disorder is critical, as it is treatable with riboflavin supplementation. We describe a 16-year-old female with a phenotype consistent with RTD3 found to have a novel heterozygous variant. Though RTD is typically considered an autosomal recessive condition, her heterozygous variant was thought to be disease causing after further genetic analysis and given her improvement in response to riboflavin supplementation. This case highlights the importance of reinterpretation of genetic testing, particularly when there is a high clinical suspicion for disease.

摘要

核黄素转运蛋白缺乏症(RTD)是一种神经退行性疾病,从婴儿期到成年期均可出现,表现为进行性轴索性神经病,其特征是出现多种神经系统症状,包括听力丧失、无力、延髓麻痹和呼吸功能不全。SLC52A2和SLC52A3基因的致病变异分别与2型和3型RTD的发病机制有关。尽早识别这种疾病至关重要,因为补充核黄素可对其进行治疗。我们描述了一名16岁女性,其表型与3型RTD一致,发现有一个新的杂合子变异。尽管RTD通常被认为是常染色体隐性疾病,但经过进一步基因分析,并鉴于她对补充核黄素的反应有所改善,其杂合子变异被认为是致病的。该病例突出了重新解读基因检测结果的重要性,尤其是在临床高度怀疑患病的情况下。

相似文献

1
A case report of riboflavin transporter deficiency: A novel heterozygous pathogenic variant in the gene.
Mol Genet Metab Rep. 2024 Jan 15;38:101051. doi: 10.1016/j.ymgmr.2024.101051. eCollection 2024 Mar.
3
Brown-Vialetto-Van Laere and Fazio-Londe syndromes: SLC52A3 mutations with puzzling phenotypes and inheritance.
Eur J Neurol. 2021 Mar;28(3):945-954. doi: 10.1111/ene.14682. Epub 2021 Jan 5.
4
An update on the genetics, clinical presentation, and pathomechanisms of human riboflavin transporter deficiency.
J Inherit Metab Dis. 2019 Jul;42(4):598-607. doi: 10.1002/jimd.12053. Epub 2019 Feb 21.
5
A Case of Brown-Vialetto-Van Laere Syndrome Due To a Novel Mutation in Gene: Clinical Course and Response to Riboflavin.
Child Neurol Open. 2017 Aug 22;4:2329048X17725610. doi: 10.1177/2329048X17725610. eCollection 2017 Jan-Dec.
6
Atypical presentations in an RTD patient and report of novel SLC52A3 and SLC52A2 mutations.
Acta Neurol Belg. 2024 Aug;124(4):1363-1370. doi: 10.1007/s13760-024-02598-7. Epub 2024 Jul 4.
9
Clinical, pathological and functional characterization of riboflavin-responsive neuropathy.
Brain. 2017 Nov 1;140(11):2820-2837. doi: 10.1093/brain/awx231.
10
Genetic, Radiologic, and Clinical Variability in Brown-Vialetto-van Laere Syndrome.
Semin Pediatr Neurol. 2018 Jul;26:2-9. doi: 10.1016/j.spen.2017.03.001. Epub 2017 Apr 5.

引用本文的文献

1
Long-Term Survival in Brown-Vialetto-Van Laere Syndrome: A Case Report Highlighting Respiratory Care.
Cureus. 2025 May 20;17(5):e84491. doi: 10.7759/cureus.84491. eCollection 2025 May.

本文引用的文献

1
Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria.
Am J Hum Genet. 2022 Dec 1;109(12):2163-2177. doi: 10.1016/j.ajhg.2022.10.013. Epub 2022 Nov 21.
2
BVVL/ FL: features caused by SLC52A3 mutations; WDFY4 and TNFSF13B may be novel causative genes.
Neurobiol Aging. 2021 Mar;99:102.e1-102.e10. doi: 10.1016/j.neurobiolaging.2020.09.021. Epub 2020 Oct 5.
3
Overview of Specifications to the ACMG/AMP Variant Interpretation Guidelines.
Curr Protoc Hum Genet. 2019 Sep;103(1):e93. doi: 10.1002/cphg.93.
4
An update on the genetics, clinical presentation, and pathomechanisms of human riboflavin transporter deficiency.
J Inherit Metab Dis. 2019 Jul;42(4):598-607. doi: 10.1002/jimd.12053. Epub 2019 Feb 21.
5
Clinical, pathological and functional characterization of riboflavin-responsive neuropathy.
Brain. 2017 Nov 1;140(11):2820-2837. doi: 10.1093/brain/awx231.
6
REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants.
Am J Hum Genet. 2016 Oct 6;99(4):877-885. doi: 10.1016/j.ajhg.2016.08.016. Epub 2016 Sep 22.
7
Analysis of protein-coding genetic variation in 60,706 humans.
Nature. 2016 Aug 18;536(7616):285-91. doi: 10.1038/nature19057.
8
Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience.
J Inherit Metab Dis. 2016 Jul;39(4):559-64. doi: 10.1007/s10545-016-9924-2. Epub 2016 Mar 14.
10
Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2.
Brain. 2014 Jan;137(Pt 1):44-56. doi: 10.1093/brain/awt315. Epub 2013 Nov 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验